Want to join the conversation?
On Oct. 28, $ICPT announced results of a 72-week Phase 2 dose ranging trial of OCA in 200 adult patients with NASH in Japan. In this trial, 202 Japanese biopsy-proven NASH patients were randomized into one of four arms to receive either a 10mg, 20mg or 40mg dose of OCA or placebo. The primary endpoints was histologic improvement.
Apple ($AAPL) reported decline in sales and profits from comparable quarter last year, attributing the decline to announcement of iPhone 7/7s. Sales and profit are being guided higher for next quarter. Apple is a solid company and will continue to dominate tech and consumer electronics segment for a while. Personally, looks like there is little downside in this investment.
Waiting with fingers crossed for $AAPL’s fourth quarter earnings.
Looking ahead to $AAPL earnings release later in the afternoon today? Gene Munster, analyst from Piper Jaffrey and the most respected authority for Apple, had this to say - "The second and slightly larger group of investors believe the tail of the iPhone 7 is irrelevant, and is betting that the iPhone 10th Anniversary will yield a jump in growth from flat to up ~15%."